IL-23 stabilizes an effector T reg cell program in the tumor microenvironment.
Tobias WertheimerPascale ZwickyLukas RindlisbacherColin SparanoMarijne VermeerBruno Marcel Silva de MeloClaudia HaftmannTamina RückertAakriti SethiStefanie SchärliAnna HuberFlorian IngelfingerCaroline XuDaehong KimPhilipp HäneAndré Fonseca da SilvaAndreas MuschaweckhNicolás Gonzalo NuñezSinduya KrishnarajahNatalie StickelRobert ZeiserMohamed OukkaThomas KornSonia TuguesBurkhard BecherPublished in: Nature immunology (2024)
Interleukin-23 (IL-23) is a proinflammatory cytokine mainly produced by myeloid cells that promotes tumor growth in various preclinical cancer models and correlates with adverse outcomes. However, as to how IL-23 fuels tumor growth is unclear. Here, we found tumor-associated macrophages to be the main source of IL-23 in mouse and human tumor microenvironments. Among IL-23-sensing cells, we identified a subset of tumor-infiltrating regulatory T (T reg ) cells that display a highly suppressive phenotype across mouse and human tumors. The use of three preclinical models of solid cancer in combination with genetic ablation of Il23r in T reg cells revealed that they are responsible for the tumor-promoting effect of IL-23. Mechanistically, we found that IL-23 sensing represents a crucial signal driving the maintenance and stabilization of effector T reg cells involving the transcription factor Foxp3. Our data support that targeting the IL-23/IL-23R axis in cancer may represent a means of eliciting antitumor immunity.